3,3'-dicarboxy-5,5'-dichloro-4,4'-dihydroxydiphenylmethane | 128626-47-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3'-dicarboxy-5,5'-dichloro-4,4'-dihydroxydiphenylmethane
• 英文别名: 3,3'-dichloro-5,5'-dicarboxy-4,4'-dihydroxydiphenylmethane；NSC 622444；5-(3-Carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid；5-[(3-carboxy-5-chloro-4-hydroxyphenyl)methyl]-3-chloro-2-hydroxybenzoic acid
• CAS: 128626-47-1
• 化学式: C₁₅H₁₀Cl₂O₆
• 分子量: 357.147
• InChiKey: BFCJNYJGIGUQJA-UHFFFAOYSA-N

物化性质

• 熔点：
  284 °C (decomp)
• 沸点：
  558.0±50.0 °C(Predicted)
• 密度：
  1.663±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,3'-dicarboxy-5,5'-dichloro-4,4'-dihydroxydiphenylmethane 在 palladium on activated charcoal 760 torr 、 氢气 作用下， 以 乙醇 、 三乙胺 为溶剂， 反应 48.0h， 以92%的产率得到5,5'-亚甲基二水杨酸
  参考文献：
  名称：

  误认为金三羧酸（ATA）结构的共价水合物的合成

  摘要：

  已经合成了三苯基甲醇6，它是公认的但不正确的金三羧酸（ATA）结构的共价水合物，并已发现在CEM-V淋巴细胞培养中可抵抗HIV-1的细胞病变作用。该合成涉及纯亚甲基二水杨酸的首次制备（5）。除了（聚合）ATA以外，三苯基甲醇6还为开发潜在的抗艾滋病药物提供了新的线索。即使在7天后，在室温下在存在过量的18氧标记水的情况下，中心碳氧6仍未交换，这表明6和1之间没有平衡。 在这些条件下。

  DOI：

  10.1016/s0040-4020(01)81957-8
• 作为产物：
  描述：

  甲基 3-氯-2-羟基苯甲酸 在 sodium hydroxide 、 硫酸 、 溶剂黄146 作用下， 以 1,4-二氧六环 为溶剂， 生成 3,3'-dicarboxy-5,5'-dichloro-4,4'-dihydroxydiphenylmethane
  参考文献：
  名称：

  Methylenedisalicylic acid derivatives: New PTP1B inhibitors that confer resistance to diet-induced obesity

  摘要：

  Methylenedisalicylic acid derivatives were synthesized and their inhibitory activities against protein tyrosine phosphalases (PTPases) examined. Two of the compounds, 8 and 9, showed K-i values of 9.4 and 6.3 mu M against PTP I B, 4- and 7-fold lower values compared to those against TC-PTP. They were reversible and slow-binding inhibitors against PTP I B. When compound 8 was fed to a mouse model, the weight gain and adipocyte fat storage induced by a high-fat-diet were significantly suppressed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.069

文献信息

• Heterobifunctional pan-selectin inhibitors
  申请人：Magnani L. John

  公开号：US20070054870A1

  公开（公告）日：2007-03-08

  Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).

  提供了用于调节体外和体内由选择素结合介导的过程的化合物和方法。更具体地描述了选择素调节剂及其用途，其中调节选择素介导功能的选择素调节剂包括特定的糖类似物，单独或与一类被称为BASAs（苯甲基氨基磺酸）的化合物或一类被称为BACAs（苯甲基氨基羧酸）的化合物中的成员相连。
• [EN] SELECTIVE INHIBITION OF THE MEMBRANE ATTACK COMPLEX OF COMPLEMENT AND C3 CONVERTASE BY LOW MOLECULAR WEIGHT COMPONENTS OF THE AURIN TRICARBOXYLIC ACID SYNTHETIC COMPLEX<br/>[FR] INHIBITION SÉLECTIVE DU COMPLEXE D'ATTAQUE MEMBRANAIRE DU COMPLÉMENT ET DE LA C3 CONVERTASE PAR DES COMPOSANTS À FAIBLE POIDS MOLÉCULAIRE DU COMPLEXE SYNTHÉTIQUE D'ACIDE PARAROSOLIQUE TRICARBOXYLIQUE
  申请人：AURIN BIOTECH INC

  公开号：WO2014009779A1

  公开（公告）日：2014-01-16

  Selective inhibition of the membrane attack complex of complement in a mammalian species, preferably human, with components of the aurin tricarboxylic acid complex of less than 1 kilodalton in molecular weight. Preferred inhibitors are aurin tricarboxylic acid, aurin quadracarboxylic acid and aurin hexacarboxylic acid. Preferred disease to be treated by elective inhibition of the membrane attack complex of complement are age-related macular degeneration, Alzheimer's disease, atherosclerosis, rheumatoid arthritis, paroxysmal nocturnal hemoglobinemia, malaria infection and multiple sclerosis.

  选择性抑制哺乳动物物种（优选人类）中分子量小于1千道尔顿的石黄酸三羧酸复合物成分的膜攻击复合物。优选的抑制剂包括石黄酸三羧酸、石黄酸四羧酸和石黄酸六羧酸。通过选择性抑制膜攻击复合物治疗的优选疾病包括年龄相关性黄斑退化、阿尔茨海默病、动脉硬化、类风湿性关节炎、周期性夜间血红蛋白尿、疟疾感染和多发性硬化症。
• Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex
  申请人：McGeer Patrick L.

  公开号：US20130035388A1

  公开（公告）日：2013-02-07

  This patent pertains to selective inhibition of assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by the membrane attack complex. These diseases include, but are not limited to, Alzheimer disease, age related macular degeneration, and atherosclerosis.

  这项专利涉及使用小于1 kDa分子量的aurin三羧酸合成复合物（ATAC）及其衍生物，有选择性地抑制补体膜攻击复合物的组装。它还涉及使用这些材料来治疗人类疾病，其中存在宿主组织自我破坏的证据，这些疾病包括但不限于阿尔茨海默病，年龄相关性黄斑变性和动脉粥样硬化。
• Treatment of age-related macular degeneration
  申请人：Aurin Biotech Inc.

  公开号：US10588879B2

  公开（公告）日：2020-03-17

  A method of treating age-related macular degeneration. The method includes the step of administering orally or parenterally an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, and/or aurin hexacarboxylic acid, wherein the method excludes administration of components of aurin tricarboxylic acid complex of greater than or equal to 1 kilodalton in molecular weight.

  一种治疗老年性黄斑变性的方法。该方法包括口服或肠外给药有效量的曙红三羧酸、曙红四羧酸和/或曙红六羧酸的步骤，其中该方法不包括给药分子量大于或等于1千道尔顿的曙红三羧酸复合物成分。
• Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex
  申请人：McGeer Patrick L.

  公开号：US10966945B2

  公开（公告）日：2021-04-06

  This patent pertains to selective inhibition of assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by the membrane attack complex. These diseases include, but are not limited to, Alzheimer disease, age related macular degeneration, and atherosclerosis.

  本专利涉及通过使用分子量小于 1 kDa 的三羧酸曙红合成复合物 (ATAC) 及其衍生物，选择性地抑制补体膜攻击复合物的组装。它还涉及使用这些材料治疗有证据表明膜攻击复合物对宿主组织造成自我破坏的人类疾病。这些疾病包括但不限于阿尔茨海默病、老年性黄斑变性和动脉粥样硬化。